



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

## Entecavir Viatris

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Commission Decision Issued <sup>2</sup> / amended on	Product Information affected <sup>3</sup>	Summary
T/0011	Transfer of Marketing Authorisation	01/03/2024	09/04/2024	SmPC, Labelling and PL	
IAIN/0012/G	This was an application for a group of variations.  A.7 - Administrative change - Deletion of manufacturing sites	27/02/2024	n/a		

<sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

<sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)				
IG/1688	A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs	15/01/2024	05/04/2024	SmPC, Labelling and PL	
N/0009	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	18/04/2023	05/04/2024	PL	
R/0008	Renewal of the marketing authorisation.	22/04/2022	21/06/2022	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Entecavir Mylan in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
IA/0007/G	<p>This was an application for a group of variations.</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p>	13/10/2021	n/a		

T/0006	Transfer of Marketing Authorisation	15/09/2021	11/10/2021	SmPC, Labelling and PL	
IB/0005/G	<p>This was an application for a group of variations.</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p>	15/01/2021	16/04/2021	SmPC, Annex II, Labelling and PL	
IAIN/0004	<p>B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing</p>	17/04/2020	16/04/2021	SmPC, Annex II, Labelling and PL	
IB/0003/G	<p>This was an application for a group of variations.</p> <p>B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site</p> <p>B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site</p>	03/05/2019	n/a		

	<p>B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products</p> <p>B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process</p>				
N/0002	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	07/03/2019	16/04/2021	PL	
IB/0001/G	<p>This was an application for a group of variations.</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate</p>	20/12/2018	n/a		